251 related articles for article (PubMed ID: 22054733)
21. Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment.
Minami Y; Kajiguchi T; Abe A; Ohno T; Kiyoi H; Naoe T
Int J Hematol; 2010 Nov; 92(4):664-6. PubMed ID: 20963643
[TBL] [Abstract][Full Text] [Related]
22. Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K; Warzocha K; Hellmann A; Skotnicki A; Prejzner W; Foryciarz K; Sacha T; Gniot M; Majewski M; Solarska I; Nowak G; Wasag B; Kobelski M; Scibiorski C; Siemiatkowski M; Lewandowska M; Komarnicki M
Pol Arch Med Wewn; 2009 Dec; 119(12):789-94. PubMed ID: 20010464
[TBL] [Abstract][Full Text] [Related]
23. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation.
Shimazu Y; Murata M; Kondo T; Minami Y; Tachibana T; Doki N; Uchida N; Ozawa Y; Yano S; Fukuda T; Kato J; Ara T; Eto T; Ishikawa J; Nakamae H; Tanaka J; Ichinohe T; Atsuta Y; Nagamura-Inoue T;
Hematol Oncol; 2022 Aug; 40(3):442-456. PubMed ID: 35394658
[TBL] [Abstract][Full Text] [Related]
24. [Outcomes of imatinib and allogeneic hematopoietic stem cell transplantation in the treatment of chronic myeloid leukemia].
Zhou M; Sha X; Qiu H; He G; Xu Y; Cen J; Pan J; Chen S; Sun A; Zhang R; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):126-8. PubMed ID: 24606653
[TBL] [Abstract][Full Text] [Related]
25. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
26. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
27. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?
Goldman J; Gordon M
Leuk Lymphoma; 2006 Jan; 47(1):1-7. PubMed ID: 16321820
[TBL] [Abstract][Full Text] [Related]
28. Overcoming kinase resistance in chronic myeloid leukemia.
Lee F; Fandi A; Voi M
Int J Biochem Cell Biol; 2008; 40(3):334-43. PubMed ID: 18401881
[TBL] [Abstract][Full Text] [Related]
29. Which TKI should be recommended as initial treatment for CML in chronic phase?
Schiffer CA
Oncology (Williston Park); 2012 Oct; 26(10):912, 914. PubMed ID: 23175997
[No Abstract] [Full Text] [Related]
30. Second-line therapy for patients with chronic myeloid leukemia resistant to first-line imatinib.
Lau A; Seiter K
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):186-96. PubMed ID: 24456839
[TBL] [Abstract][Full Text] [Related]
31. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
[TBL] [Abstract][Full Text] [Related]
32. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation.
Suttorp M; Millot F
Hematology Am Soc Hematol Educ Program; 2010; 2010():368-76. PubMed ID: 21239821
[TBL] [Abstract][Full Text] [Related]
33. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
34. Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
O'Hare T; Eide CA; Deininger MW
Clin Lymphoma Myeloma; 2007 Mar; 7 Suppl 3():S120-30. PubMed ID: 17382021
[TBL] [Abstract][Full Text] [Related]
35. 3. Imatinib therapy in chronic myelogenous leukemia.
Jinnai I
Intern Med; 2007; 46(2):95-7. PubMed ID: 17220607
[No Abstract] [Full Text] [Related]
36. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ
J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747
[TBL] [Abstract][Full Text] [Related]
37. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
Cornelison AM; Kantarjian H; Cortes J; Jabbour E
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
[TBL] [Abstract][Full Text] [Related]
38. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
39. Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era.
Warlick E; Ahn KW; Pedersen TL; Artz A; de Lima M; Pulsipher M; Akpek G; Aljurf M; Cahn JY; Cairo M; Chen YB; Cooper B; Deol A; Giralt S; Gupta V; Khoury HJ; Kohrt H; Lazarus HM; Lewis I; Olsson R; Pidala J; Savani BN; Seftel M; Socié G; Tallman M; Ustun C; Vij R; Vindeløv L; Weisdorf D
Blood; 2012 Apr; 119(17):4083-90. PubMed ID: 22408257
[TBL] [Abstract][Full Text] [Related]
40. Restoration of donor chimerism by nilotinib in a chronic myeloid leukaemia patient post mutation-associated imatinib mesylate resistance and allogeneic stem cell transplant failure.
O'Connor LM; Langabeer S; McCann SR; Conneally E
Bone Marrow Transplant; 2008 Dec; 42(12):833-5. PubMed ID: 18711344
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]